In its fourth quarter 2024 investor letter, Sound Shore Management emphasized stocks such as Teva Pharmaceutical Industries Limited (NYSE:TEVA). Headquartered in Tel Aviv, Israel, Teva ...

In its fourth quarter 2024 investor letter, Sound Shore Management emphasized stocks such as Teva Pharmaceutical Industries Limited (NYSE:TEVA). Headquartered in Tel Aviv, Israel, Teva Pharmaceutical ...

AMSTERDAM, Feb. 20, 2025 (GLOBE NEWSWIRE) -- New research by Teva Pharmaceuticals Europe shows that 46% of generic medicines from the EU Critical List of Medicines are supplied by only one provider.

In February 2025, Teva Pharmaceuticals and Alvotech announced the U.S. launch of SELARSDI™ (ustekinumab-aekn), a biosimilar to Stelara® (ustekinumab), following FDA approval and a provisional ...

TEL AVIV, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will conduct a conference call and live webcast at 8 am E.T ...

Actress Nargis Fakhri has tied the knot with her longtime boyfriend, US-based entrepreneur Tony Beig, in a private ceremony at the luxurious Beverly Hills Hotel in Los Angeles. The couple ...

Actress Nargis Fakhri and businessman Tony Beig reportedly got married in a private ceremony in Los Angeles. The wedding was a quiet affair with only family and close friends in attendance.

Actor Nargis Fakhri has reportedly tied the knot with her long-time beau and US-based entrepreneur Tony Beig. Pictures from the couple’s wedding have surfaced online. Although Nargis has not ...

Teva and Alvotech's Selarsdi, like Stelara, is approved for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, and moderately to severely active Crohn's disease and ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Short interest in Teva Pharmaceutical Industries Ltd (NYSE:TEVA) increased during the last reporting period, rising from 23.22M to 27.13M. This put 2.41% of the company's publicly available shares ...